References
- BlethenSLBaptistaJKuntzeJFoleyTLaFranchiSJohansonAAdult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genentech Growth Study GroupJ Clin Endocrinol Metab19978224184209024229
- RossJCzernichowPBillerBMGrowth hormone: health considerations beyond height gainPediatrics20101254e906e91820308212
- RadovickSDiVallSApproach to the growth hormone-deficient child during transition to adulthoodJ Clin Endocrinol Metab20079241195120017409338
- LongobardiSCuocoloAMerolaBLeft ventricular function in young adults with childhood and adulthood onset growth hormone deficiencyClin Endocrinol (Oxf)19984821371439579223
- BootAMEngelsMABoermaGJKrenningEPDe Muinck Keizer-SchramaSMChanges in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiencyJ Clin Endocrinol Metab1997828242324289253311
- CapaldoBPattiLOlivieroUIncreased arterial intima-media thickness in childhood-onset growth hormone deficiencyJ Clin Endocrinol Metab1997825137813819141519
- MerolaBCittadiniAColaoACardiac structural and functional abnormalities in adult patients with growth hormone deficiencyJ Clin Endocrinol Metab1993776165816618263155
- KappelgaardAMBojesenASkydsgaardKSjögrenILaursenTLiquid growth hormone: preservatives and buffersHorm Res200462 Suppl 39810315539807
- RoehrBThe many faces of human growth hormoneBETA2003154121612691033
- BazaloGRJoshiAVGermakJComparison of human growth hormone products’ cost in pediatric and adult patients. A budgetary impact modelManag Care2007169455117969748
- LaursenTHansenBFiskerSPain perception after subcutaneous injections of media containing different buffersBasic Clin Pharmacol Toxicol200698221822116445598
- FuchsGSMikkelsenSKnudsenTKKappelgaardAMEase of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability testClin Ther200931122906291420110030
- PfütznerAHartmannKWinterFFuchsGSKappelgaardAMRohrerTRIntuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patientsClin Ther201032111918193421095487
- KappelgaardAMMikkelsenSKnudsenTKFuchsGSPatient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patientsJ Pediatr Endocrinol Metab2011247–848949621932587
- KappelgaardAMMikkelsenSBaggerCFuchsGSChildren and adolescent acceptability of a new device system to administer human growth hormone- a pilot studyJ Pediatr Endocrinol Metab2012253–428529422768658
- LindsayRFeldkampMHarrisDRobertsonJRallisonMUtah Growth Study: growth standards and the prevalence of growth hormone deficiencyJ Pediatr1994125129358021781
- National Institute for Clinical ExcellenceTechnology Appraisal 64: Human growth hormone (somatropin) in adults with growth hormone deficiency Available from: http://www.nice.org.uk/nicemedia/live/11504/32665/32665.pdfAccessed June 4, 2013
- International Organization for StandardizationNeedle-based injection systems for medical use. Requirements and test methods. Part 1: Needle-based injection systems Available from: http://www.iso.org/iso/home/store/catalogue_ics/catalogue_detail_ics.htm?csnumber=52525Accessed June 26, 2013
- European Directorate for the Quality of MedicinesEuropean Pharmacopoeia Section 2.2.5: Relative density Available from: http://www.edqm.eu/site/european-pharmacopoeia-publications-1401.htmlAccessed June 26, 2013
- Novo Nordisk Pharma LtdClinical trial NCT01604161Non-interventional study of patients using Norditropin®for growth hormone deficiency or Turner Syndrome (NordiPAD) Available from: http://clinicaltrials.gov/ct2/show/NCT01604161Accessed June 6, 2013
- HöybyeCSävendahlLChristesenHTThe NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)Clin Epidemiol2013511912723658497
- European Medicines AgencyGuideline 3 AQ11 A: specifications and control tests on the finished product1992 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003368.pdfAccessed June 26, 2013
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human UseICH Harmonised Tripartite Guideline: pharmaceutical development Q8(R2)2009 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdfAccessed June 26, 2013